Cargando…
Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2
The SARS-CoV-2 virus is currently the most serious challenge to global public health. Its emergence has severely disrupted the functioning of health services and the economic and social situation worldwide. Therefore, new diagnostic and therapeutic tools are urgently needed to allow for the early de...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836149/ https://www.ncbi.nlm.nih.gov/pubmed/35163338 http://dx.doi.org/10.3390/ijms23031412 |
_version_ | 1784649606038028288 |
---|---|
author | Wandtke, Tomasz Wędrowska, Ewelina Szczur, Marcin Przybylski, Grzegorz Libura, Marek Kopiński, Piotr |
author_facet | Wandtke, Tomasz Wędrowska, Ewelina Szczur, Marcin Przybylski, Grzegorz Libura, Marek Kopiński, Piotr |
author_sort | Wandtke, Tomasz |
collection | PubMed |
description | The SARS-CoV-2 virus is currently the most serious challenge to global public health. Its emergence has severely disrupted the functioning of health services and the economic and social situation worldwide. Therefore, new diagnostic and therapeutic tools are urgently needed to allow for the early detection of the SARS-CoV-2 virus and appropriate treatment, which is crucial for the effective control of the COVID-19 disease. The ideal solution seems to be the use of aptamers—short fragments of nucleic acids, DNA or RNA—that can bind selected proteins with high specificity and affinity. They can be used in methods that base the reading of the test result on fluorescence phenomena, chemiluminescence, and electrochemical changes. Exploiting the properties of aptamers will enable the introduction of rapid, sensitive, specific, and low-cost tests for the routine diagnosis of SARS-CoV-2. Aptamers are excellent candidates for the development of point-of-care diagnostic devices and are potential therapeutic tools for the treatment of COVID-19. They can effectively block coronavirus activity in multiple fields by binding viral proteins and acting as carriers of therapeutic substances. In this review, we present recent developments in the design of various types of aptasensors to detect and treat the SARS-CoV-2 infection. |
format | Online Article Text |
id | pubmed-8836149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88361492022-02-12 Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 Wandtke, Tomasz Wędrowska, Ewelina Szczur, Marcin Przybylski, Grzegorz Libura, Marek Kopiński, Piotr Int J Mol Sci Review The SARS-CoV-2 virus is currently the most serious challenge to global public health. Its emergence has severely disrupted the functioning of health services and the economic and social situation worldwide. Therefore, new diagnostic and therapeutic tools are urgently needed to allow for the early detection of the SARS-CoV-2 virus and appropriate treatment, which is crucial for the effective control of the COVID-19 disease. The ideal solution seems to be the use of aptamers—short fragments of nucleic acids, DNA or RNA—that can bind selected proteins with high specificity and affinity. They can be used in methods that base the reading of the test result on fluorescence phenomena, chemiluminescence, and electrochemical changes. Exploiting the properties of aptamers will enable the introduction of rapid, sensitive, specific, and low-cost tests for the routine diagnosis of SARS-CoV-2. Aptamers are excellent candidates for the development of point-of-care diagnostic devices and are potential therapeutic tools for the treatment of COVID-19. They can effectively block coronavirus activity in multiple fields by binding viral proteins and acting as carriers of therapeutic substances. In this review, we present recent developments in the design of various types of aptasensors to detect and treat the SARS-CoV-2 infection. MDPI 2022-01-26 /pmc/articles/PMC8836149/ /pubmed/35163338 http://dx.doi.org/10.3390/ijms23031412 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Wandtke, Tomasz Wędrowska, Ewelina Szczur, Marcin Przybylski, Grzegorz Libura, Marek Kopiński, Piotr Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 |
title | Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 |
title_full | Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 |
title_fullStr | Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 |
title_full_unstemmed | Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 |
title_short | Aptamers—Diagnostic and Therapeutic Solution in SARS-CoV-2 |
title_sort | aptamers—diagnostic and therapeutic solution in sars-cov-2 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836149/ https://www.ncbi.nlm.nih.gov/pubmed/35163338 http://dx.doi.org/10.3390/ijms23031412 |
work_keys_str_mv | AT wandtketomasz aptamersdiagnosticandtherapeuticsolutioninsarscov2 AT wedrowskaewelina aptamersdiagnosticandtherapeuticsolutioninsarscov2 AT szczurmarcin aptamersdiagnosticandtherapeuticsolutioninsarscov2 AT przybylskigrzegorz aptamersdiagnosticandtherapeuticsolutioninsarscov2 AT liburamarek aptamersdiagnosticandtherapeuticsolutioninsarscov2 AT kopinskipiotr aptamersdiagnosticandtherapeuticsolutioninsarscov2 |